Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.39 |
| ▸ | KLK1 | P06870 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24282829 | 0.91 | CA1 (0.43) | CA1CA2ACHEATMCTSL | |
| SCHEMBL21669244 | 0.91 | CA1 (0.44) | CA1CA2ACHEATMCTSL | |
| SCHEMBL21669240 | 0.88 | CA1 (0.42) | CA1CA2ACHEATMCTSL | |
| SCHEMBL24282891 | 0.86 | TRPM8 (0.44) | ATMCTSLCTSSTOP2ATOP2B | |
| SCHEMBL21669352 | 0.83 | KMT2A (0.41) | ELANELMNACYP3A4MEN1KMT2A | |
| SCHEMBL21669232 | 0.83 | PPARG (0.39) | CA1CA2CTSSMMP13ELANE | |
| SCHEMBL21669236 | 0.82 | CA1 (0.43) | CA1CA2ACHEATMCTSL | |
| SCHEMBL21669256 | 0.80 | CA1 (0.45) | CA1CA2ACHEATMCTSL | |
| SCHEMBL24283208 | 0.79 | TRPM8 (0.48) | ATMCTSLCTSS | |
| SCHEMBL21669296 | 0.78 | KMT2A (0.38) | ELANELMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829568-B1 | SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS | ALZHEON INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20220087967-A1 | SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2022-03-24 | — | — | US | disclosed |
| WO-2020028348-A1 | SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. (US) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087967-A1 | SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS | PSEN1, APP, PSEN2 | CA1 713/4885CA2 2469/4885ACHE 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.